ERBB2 and breast carcinoma: In a preclinical mouse model of HER2+ breast cancer, class II HER2 peptide pulsed DC1 (Class II HER2-DC1) drove CD4+ and CD8+ T cells infiltrating into tumors and delayed tumor growth.